sodium-pertechnetate-tc-99m and Raynaud-Disease

sodium-pertechnetate-tc-99m has been researched along with Raynaud-Disease* in 2 studies

Trials

1 trial(s) available for sodium-pertechnetate-tc-99m and Raynaud-Disease

ArticleYear
Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
    European journal of clinical pharmacology, 1988, Volume: 34, Issue:3

    The severity of the peripheral vasopastic condition in 10 patients with Raynaud's phenomenon was investigated using scintigraphy of both hands. 99MTc-pertechnetate was used as a diffusable tracer and scintigrams were recorded with normal hand skin temperature and following immersion of the hands in ice-cold water. Cold provocation resulted in a marked reduction of the rate of blood inflow and tissue perfusion in affected hands. The selective peripheral S2-antagonist ketanserin and placebo were administered intra-arterially according to a double-blind cross-over design. As compared to placebo, ketanserin significantly improved the rate of inflow following cold provocation, and it increased tissue perfusion in the hands of the patients to values normally observed in healthy individuals. The results support the use of ketanserin in the treatment of Raynaud's phenomenon.

    Topics: Adult; Aged; Aged, 80 and over; Female; Hand; Humans; Injections, Intra-Arterial; Ketanserin; Male; Middle Aged; Radionuclide Imaging; Raynaud Disease; Regional Blood Flow; Skin; Skin Temperature; Sodium Pertechnetate Tc 99m

1988

Other Studies

1 other study(ies) available for sodium-pertechnetate-tc-99m and Raynaud-Disease

ArticleYear
Diagnosis of Raynaud's phenomenon by
    Rheumatology international, 2016, Volume: 36, Issue:12

    We assess the usefulness of

    Topics: Adult; Aged; Female; Hand; Humans; Male; Middle Aged; Perfusion Imaging; Pilot Projects; Raynaud Disease; Scleroderma, Systemic; Sensitivity and Specificity; Sodium Pertechnetate Tc 99m

2016